Recent perspectives on the role of nutraceuticals as cholesterol-lowering agents

Current Opinion in Lipidology

Volumn 28, Issue 6, 2017, Pages 495-501

  Ward, Natalie ^a,b   Sahebkar, Amirhossein ^c   Banach, MacIej ^d,e   Watts, Gerald ^b,f  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^f ROYAL PERTH HOSPITAL   (Australia)

Author keywords

dyslipidemia; low density lipoprotein; nutraceuticals; total cholesterol

Indexed keywords

BERBERINE; CHOLESTIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PHYTOSTEROL; POLICOSANOL; CHOLESTEROL;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DIETARY FIBER; HUMAN; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; BLOOD; DIETARY SUPPLEMENT; DRUG INTERACTION;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; HUMANS;

EID: 85030711401     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000455     Document Type: Review

References (50)

1. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
2. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-Analysis. JAMA 2016; 316:1289-1297.
3. European Association for Cardiovascular Prevention & Rehabilitation. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32:1769-1818.
4. Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2016; 134:e468-e495.
5. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376:1713-1722.
6. Banach M, Stulc T, Dent R, Toth PP. Statin nonadherence and residual cardiovascular risk: there is need for substantial improvement. Int J Cardiol 2016; 225:184-196.
7. Serban MC, Colantonio LD, Manthripragada AD, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am College of Cardiol 2017; 69:1386-1395.
8. Barbagallo CM, Cefalu AB, Noto D, Averna MR. Role of nutraceuticals in hypolipidemic therapy. Front Cardiovasc Med 2015; 2:22.
9. Sahebkar A, Serban MC, Gluba-Brzozka A, et al. Lipid-modifying effects of nutraceuticals: an evidence-based approach. Nutrition 2016; 32:1179-1192.
10. Mannarino MMS, Pirro M. Nutraceuticals for the treatment of hypercholesterolaemia. Eur J Internal Med 2014; 25:592-599.
11. Hunter PM, Hegele RA. Functional foods and dietary supplements for the management of dyslipidaemia. Nat Rev Endocrinol 2017; 13:278-288.
12. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004; 10:1344-1351.
13. Dong H, Zhao Y, Zhao L, Lu F. The effects of berberine on blood lipids: a systemic review and meta-Analysis of randomized controlled trials. Planta Med 2013; 79:437-446.
14. Kong WJ, Wei J, Zuo ZY, et al. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism 2008; 57:1029-1037.
15. Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-Analysis. Evid Based Complement Alternat Med 2012; 2012:591654.
16. Chen ZY, Jiao R, Ma KY. Cholesterol-lowering nutraceuticals and functional foods. J Agric Food Chem 2008; 56:8761-8773.
17. Brouwers JR, Roeters van Lennep JE, Maas AH. ['Red yeast rice' as a cholesterol-lowering substance? Caution is warranted]. Nederlands tijdschrift voor geneeskunde 2016; 160:D99.
18. Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008; 101:1689-1693.
19. Gylling H, Plat J, Turley S, et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 2014; 232:346-360.
20. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369:1090-1098.
21. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multicenter, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011; 108:682-690.
22. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012; 110:984-992.
23. Bhatt DL, Steg PG, Brinton EA, et al. Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial. Clin Cardiol 2017; 40:138-148.
24. Panahi Y, Khalili N, Hosseini MS, et al. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Compl Therap Med 2014; 22:851-857.
25. Hooper L, Kroon PA, Rimm EB, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-Analysis of randomized controlled trials. Am J Clin Nutr 2008; 88:38-50.
26. Taku K, Umegaki K, Sato Y, et al. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-Analysis of 11 randomized controlled trials. Am J Clin Nutr 2007; 85:1148-1156.
27. Zheng XX, Xu YL, Li SH, et al. Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-Analysis of 14 randomized controlled trials. Am J Clin Nutr 2011; 94:601-610.
28. Kim A, Chiu A, Barone MK, et al. Green tea catechins decrease total and lowdensity lipoprotein cholesterol: a systematic review and meta-Analysis. J Am Diet Assoc 2011; 111:1720-1729.
29. Onakpoya I, Spencer E, Heneghan C, Thompson M. The effect of green tea on blood pressure and lipid profile: a systematic review and meta-Analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014; 24:823-836.
30. Momose Y, Maeda-Yamamoto M, Nabetani H. Systematic review of green tea epigallocatechin gallate in reducing low-density lipoprotein cholesterol levels of humans. Int J Food Sci Nutr 2016; 67:606-613.
31. Pan A, Yu D, Demark-Wahnefried W, et al. Meta-Analysis of the effects of flaxseed interventions on blood lipids. Am J Clin Nutr 2009; 90:288-297.
32. AbuMweis SS, Jew S, Ames NP. beta-glucan from barley and its lipid-lowering capacity: a meta-Analysis of randomized, controlled trials. Eur J Clin Nutr 2010; 64:1472-1480.
33. Sood N, Baker WL, Coleman CI. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-Analysis. Am J Clin Nutr 2008; 88:1167-1175.
34. Cicero AF, Colletti A. Combinations of phytomedicines with different lipid lowering activity for dyslipidemia management: The available clinical data. Phytomedicine 2016; 23:1113-1118.
35. Patti AM, Toth PP, Giglio RV, et al. Nutraceuticals as an important part of combination therapy in dyslipidaemia. Curr Pharma Design 2017. [Epub ahead of print]
36. Affuso F, Ruvolo A, Micillo F, et al. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis 2010; 20:656-661.
37. Cicero AF, Derosa G, Pisciotta L, et al. Testing the short-term efficacy of a lipid-lowering nutraceutical in the setting of clinical practice: a multicenter study. J Med Food 2015; 18:1270-1273.
38. Pisciotta L, Bellocchio A, Bertolini S. Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. Lipids Health Dis 2012; 11:123.
39. Campolongo GRCV, Raparelli V, Spoletini I, et al. The combination of nutraceutical and simvastatin enhances the effect of simvastatin alone in normalising lipid profile without side effects in patients with ischemic heart disease. IJC Metab Endocrine 2016; 11:3-6.
40. Ruscica M, Gomaraschi M, Mombelli G, et al. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus. J Clin Lipidol 2014; 8:61-68.
41. Sola R, Valls RM, Puzo J, et al. Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial. PLoS One 2014; 9:e101978.
42. Pirro M, Mannarino MR, Bianconi V, et al. The effects of a nutraceutical combination on plasma lipids and glucose: a systematic review and metaanalysis of randomized controlled trials. Pharmacol Res 2016; 110:76-88.
43. Millan J, Cicero AF, Torres F, Anguera A. Effects of a nutraceutical combination containing berberine (BRB), policosanol, and red yeast rice (RYR), on lipid profile in hypercholesterolemic patients: A meta-Analysis of randomised controlled trials. Clinica e investigacion en arteriosclerosis 2016; 28:178-187.
44. Barrios V, Escobar C, Cicero AF, et al. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: review of the clinical evidence. Atheroscler Suppl 2017; 24:1-15.
45. Moss JW, Ramji DP. Nutraceutical therapies for atherosclerosis. Nat Rev Cardiol 2016; 13:513-532.
46. Fuentes MC, Lajo T, Carrion JM, Cune J. Cholesterol-lowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in hypercholesterolaemic adults. Br J Nutr 2013; 109:1866-1872.
47. Bosch M, Fuentes MC, Audivert S, et al. Lactobacillus plantarum CECT 7527, 7528 and 7529: probiotic candidates to reduce cholesterol levels. J Sci Food Agric 2014; 94:803-809.
48. Panahi Y, Kianpour P, Mohtashami R, et al. Efficacy and safety of phytosomal curcumin in non-Alcoholic fatty liver disease: a randomized controlled trial. Drug Res (Stuttg) 2017; 67:244-251.
49. Davi G, Santilli F, Patrono C. Nutraceuticals in diabetes and metabolic syndrome. Cardiovasc Therap 2010; 28:216-226.
50. Cicero ACA, Bajraktari G, Decamps O, et al., On behalf of the International Lipid Expert Panel. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Arch Med Sci Nutr Rev 2017. [in press]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379380/.